CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
原发性与 CAR-T 相关继发性 T 细胞恶性肿瘤中克隆性造血相关基因的基因组特征
英文原题：Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.
查看英文原题
Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞治疗后发生的继发性T细胞白血病和淋巴瘤（TCL）日益受到关注，但其发病机制尚未充分了解。风险因素可能是多因素的，包括既往抗癌治疗暴露、插入突变、潜在致癌突变和克隆性造血（CH）。本研究分析CAR-T 细胞相关继发性TCL的分子特征，并与原发性TCL进行比较。我们还考察CH的作用及其与TCL发病相关体细胞突变的相互影响，这些分析对患者风险分层、监测和治疗具有重要意义。
展开英文摘要原文
Secondary T-cell leukemias and lymphomas (TCLs) manifesting after chimeric antigen receptor (CAR) T-cell therapy represent an emerging concern, but their pathogenesis remains poorly understood. Risk factors are multifactorial and potentially include previous exposure to anticancer treatments, insertional mutagenesis, latent oncogenic mutations, and clonal hematopoiesis (CH). In this study, the molecular features of CAR T-cell-associated secondary TCLs are analyzed and contrasted with those of primary TCLs.
Our study also examines the role of CH and its interplay with somatic mutations that are associated with TCL pathogenesis, with implications for patient risk stratification, monitoring, and treatment.
论文信息
- 作者
- Park JJ、Avigan ZM、Dong MB、Nguyen CV、Guitart J、Kotecha RR、Perica K、Parekh S
- 第一作者单位
- Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL.United States
- 通讯作者单位
- Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.United States
- 期刊
- Blood neoplasia2026 Aug
- 原文标识
- PubMed 42382045 · DOI 10.1016/j.bneo.2026.100244
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →